{"id":40793,"date":"2020-10-13T08:40:14","date_gmt":"2020-10-13T03:10:14","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=40793"},"modified":"2020-10-13T08:40:14","modified_gmt":"2020-10-13T03:10:14","slug":"antiarrhythmic-drug-classification","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/","title":{"rendered":"Antiarrhythmic drug classification"},"content":{"rendered":"<h2><span style=\"color: #008000;\">Antiarrhythmic drug classification<\/span><\/h2>\n<p><iframe loading=\"lazy\" src=\"https:\/\/www.youtube.com\/embed\/AVRqLN8TMRc\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p><em><span style=\"color: #0000ff;\">Click on the play button for the audio commentary.<\/span><\/em><\/p>\n<p>The popular Vaughan Williams classification was published in 1975 [1]. It is still being used by most of us. The Sicilian Gambit published in 1991 [2] has not been so popular because of its complexity.<\/p>\n<p>Vaughan Williams classification is approximately as follows:<\/p>\n<p><em>\u00a0Class I: Sodium channel blockers<\/em><\/p>\n<p>\u25e6a: Moderate Na channel block. e.g. Quinidine, Disopyramide<\/p>\n<p>\u25e6b: Weak Na channel block. e.g. Lignocaine, Mexiletine<\/p>\n<p>\u25e6c: Marked Na channel block. e.g. Flecainide, Propafenone<\/p>\n<p><em>\u00a0Class II: Beta blockers<\/em><\/p>\n<p>\u00a0<em>Class III: Potassium channel blockers:<\/em> Amiodarone, Sotalol, Ibutilide<\/p>\n<p>\u00a0<em>Class IV: Calcium channel blockers<\/em><\/p>\n<p>In 2018, an extended update (Modernized Classification of Cardiac Antiarrhythmic Drugs) was published by Ming Lei et al [3]. This classification has classes I to VII of which class VII is a group of upstream is a group of upstream target modulators and not direct anti arrhythmic drugs. The whole classification is quite extensive. It is approximately like this:<\/p>\n<p>\u00a0<em>Class 0:<\/em> HCN channel blockers: e.g. Ivabradine<\/p>\n<p><em>\u00a0Class I:<\/em> Voltage gated sodium channel blockers<\/p>\n<p>\u25e6a: Nav 1.5 open state, intermediate dissociation. e.g. Quinidine, Disopyramide<\/p>\n<p>\u25e6b: Nav 1.5 open state, rapid dissociation. e.g. Lignocaine, Mexiletine<\/p>\n<p>\u25e6c: Nav 1.5 inactivated state, slow dissociation. e.g. Flecainide, Propafenone<\/p>\n<p>\u25e6d: Nav 1.5 late current. e.g. Ranolazine<\/p>\n<p>\u00a0<em>Class II:<\/em> Autonomic inhibitors and activators<\/p>\n<p>\u25e6a: Nonselective \u03b2 inhibitor: Carvedilol, Propranolol; Selective \u03b21 inhibitor: Metoprolol<\/p>\n<p>\u25e6b: Nonselective \u03b2 activator: Isoproterenol<\/p>\n<p>\u25e6c: Muscarinic M2 inhibitor: Atropine, Hyoscine, Scopolamine<\/p>\n<p>\u25e6d: Muscarinic M2 activator: Pilocarpine, Digoxin<\/p>\n<p>\u25e6e: Adenosine A1 activator: Adenosine, ATP<\/p>\n<p><em>Class III:<\/em> Voltage dependent potassium channel openers and blockers\u00a0<\/p>\n<p>\u00a0 IIIa: Nonselective potassium channel blocker: Amiodarone, Dronedarone<\/p>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 HERG blocker (I<sub>Kr<\/sub>): Dofetilide, Ibutilide, Sotalol<\/p>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 I<sub>Ks<\/sub> blocker: No clinically approved drugs in use<\/p>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 I<sub>Kur<\/sub> blocker: Vernakalant<\/p>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 I<sub>to1<\/sub> blocker: Tedisamil (Under regulatory review for AF conversion)<\/p>\n<p>\u00a0 IIIb: I<sub>KATP<\/sub> opener: Nicorandil, Pinacidil<\/p>\n<p>\u00a0 IIIc: I<sub>KACh<\/sub> blocker: BMS 914392 (Under regulatory review for AF Rx)<\/p>\n<p><em>Class IV:<\/em> Calcium handling modulators<\/p>\n<p>\u00a0 IVa: Surface membrane Ca<sup>2+<\/sup> channel blocker<\/p>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0Non selective: Bepridil<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 I<sub>CaL<\/sub>\u00a0blocker: Verapamil, Diltiazem<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 I<sub>CaT<\/sub>\u00a0blocker: No clinically approved drugs in use\u00a0<\/p>\n<p>\u00a0 IVb: Intracellular Ca<sup>2+<\/sup> channel blocker:<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SR RyR2- Ca<sup>2+<\/sup> channel blocker: Flecainide, Propafenone (Overlaps Ic)<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IP3R- Ca<sup>2+<\/sup> channel blocker: No clinically approved drugs in use<\/p>\n<p>\u00a0 IVc:\u00a0 Sarcoplasmic reticular Ca<sup>2+<\/sup>-ATPase activator: No approved drugs<\/p>\n<p>\u00a0 IVd: Surface membrane ion exchange inhibitor: No approved drugs<\/p>\n<p>\u00a0 IVe: Phosphokinase and phosphorylase inhibitors: No approved drugs<\/p>\n<p><em>Class V:<\/em> Mechanosensitive channel blockers<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 TRPC3\/TRPC6 blocker: N-(p-amylcinnamoyl)anthranilic acid- on trial<\/p>\n<p><em>Class VI:<\/em> Gap junction channel blockers<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cx (Cx40, Cx43, Cx45) blocker: Carbenoxolone \u2013 under investigation<\/p>\n<p><em>Class VII:<\/em> Upstream target modulators<\/p>\n<p>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ACEI, ARB, Omega-3 fatty acids, Statins<\/p>\n<p>This classification is also a bit too extensive and difficult for routine clinical use. Moreover this includes several subclasses in which no drug is available. Hence this is a futuristic classification hoping that drugs in those groups will become available later. Group VII contains drugs with upstream action and are not direct antiarrhythmic agents. If these redundant groups are removed, this classification can become much simpler. Of course, an updated classification is needed as several new drugs with different mechanisms of action have been introduced after the original classification in 1975. It may also be noted that some drugs like Flecainide comes in two groups. That problem was there earlier also as Amiodarone had all the classes of actions and Sotalol was both a beta blocker and a class III agent.<\/p>\n<p><strong><span style=\"color: #0000ff;\">References<\/span><\/strong><\/p>\n<ol>\n<li>E M Vaughan Williams. Classification of antidysrhythmic drugs. Pharmacol Ther B. 1975;1(1):115-38.\u00a0<\/li>\n<li>Task Force of the Working Group on Arrhythmias, the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms.Circulation. 1991; 84:1831\u20131851.<\/li>\n<li>Ming Lei, Lin Wu, Derek A Terrar, Christopher L-H Huang. <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.118.035455\">Modernized Classification of Cardiac Antiarrhythmic Drugs<\/a>. Circulation. 2018 Oct 23;138(17):1879-1896.<\/li>\n<\/ol>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antiarrhythmic drug classification Click on the play button for the audio commentary. The popular Vaughan Williams classification was published in 1975 [1]. It is still being used by most of us. The Sicilian Gambit published in 1991 [2] has not been so popular because of its complexity. Vaughan Williams classification is approximately as follows: \u00a0Class [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":40801,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[6],"tags":[],"class_list":["post-40793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ecg-electrophysiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antiarrhythmic drug classification - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antiarrhythmic drug classification - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Antiarrhythmic drug classification Click on the play button for the audio commentary. The popular Vaughan Williams classification was published in 1975 [1]. It is still being used by most of us. The Sicilian Gambit published in 1991 [2] has not been so popular because of its complexity. Vaughan Williams classification is approximately as follows: \u00a0Class [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-13T03:10:14+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Antiarrhythmic drug classification\",\"datePublished\":\"2020-10-13T03:10:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/\"},\"wordCount\":616,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"ECG \\\/ Electrophysiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/\",\"name\":\"Antiarrhythmic drug classification - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2020-10-13T03:10:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/antiarrhythmic-drug-classification\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antiarrhythmic drug classification\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antiarrhythmic drug classification - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/","og_locale":"en_US","og_type":"article","og_title":"Antiarrhythmic drug classification - All About Cardiovascular System and Disorders","og_description":"Antiarrhythmic drug classification Click on the play button for the audio commentary. The popular Vaughan Williams classification was published in 1975 [1]. It is still being used by most of us. The Sicilian Gambit published in 1991 [2] has not been so popular because of its complexity. Vaughan Williams classification is approximately as follows: \u00a0Class [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2020-10-13T03:10:14+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Antiarrhythmic drug classification","datePublished":"2020-10-13T03:10:14+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/"},"wordCount":616,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#primaryimage"},"thumbnailUrl":"","articleSection":["ECG \/ Electrophysiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/","url":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/","name":"Antiarrhythmic drug classification - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#primaryimage"},"thumbnailUrl":"","datePublished":"2020-10-13T03:10:14+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/antiarrhythmic-drug-classification\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Antiarrhythmic drug classification"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/40793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=40793"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/40793\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=40793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=40793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=40793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}